Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus XULTOPHY 100 3 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus XULTOPHY 100 3 6.
BYDUREON vs XULTOPHY 100/3.6
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Xultophy 100/3.6 is a combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist). Insulin degludec binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production. Liraglutide activates GLP-1 receptors, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
2 mg subcutaneously once every 7 days (weekly).
Subcutaneous injection once daily, starting at 10 units (10 units insulin degludec and 3.6 mcg liraglutide). Titrate by 2 units every 3-4 days based on fasting plasma glucose to a maximum of 50 units daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Insulin degludec: ~25 hours (range 22-28 hours); liraglutide: ~13 hours. The ultra-long half-life of insulin degludec allows once-daily dosing with flat activity profile.
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Renal: insulin degludec and liraglutide are cleared primarily via degradation, with less than 2% excreted unchanged renally. Fecal: negligible.
Category C
Category C
Antidiabetic
Antidiabetic